| Outcome Measures: |
Primary: Proportion of participants who experienced 1 or more treatment-emergent AEs, Up to Day 43 +/- 2 days|Proportion of participants who discontinued study medication due to an AE, Up to Day 43 +/- 2 days | Secondary: Area under the concentration-time curve [AUC] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|AUC of plasma K-833, when co-administered with K-757, Days 1, 28, 42|Maximum concentration [Cmax] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|Cmax of plasma K-833, when co-administered with K-757, Days 1, 28, 42|Time of maximum concentration [Tmax] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|Tmax of plasma K-833, when co-administered with K-757, Days 1, 28, 42|Clearance [Cl] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|Cl of plasma K-833, when co-administered with K-757, Days 1, 28, 42|Volume of distribution at steady-state [Vdss] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|Vdss of plasma K-833, when co-administered with K-757, Days 1, 28, 42|Half-life [t1/2] of plasma K-757, when co-administered with K-833, Days 1, 28, 42|t1/2 of plasma K-833, when co-administered with K-757, Days 1, 28, 42
|
